Huntington’s disease: danger of repeated DNA sequences
Scientists find a way to slow the progression of Huntington’s disease by analysing DNA and find the basis of a potential treatment.
List view / Grid view
Scientists find a way to slow the progression of Huntington’s disease by analysing DNA and find the basis of a potential treatment.
Researchers pinpoint connections of risk variants with microglia functions that are important for Alzheimer’s disease (AD).
Researchers find genetic explanation for increased risk of developing second cancers.
This September edition of our Women in Stem series spotlights Dr Emily Leproust, CEO of Twist Bioscience. Dr Leproust began her STEM journey from a background in chemistry, eventually leading her to the forefront of DNA synthesis technology. She co-founded Twist Bioscience in 2013, now a thriving company reporting substantial…
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
Some individuals may experience more severe symptoms when infected with the same virus compared to others. The reasons behind this variability are not yet fully understood. While viral factors, such as differences in the virus strain, do play a role, they cannot account for the diverse responses observed among individuals…
A recent study sheds light on the potential of artificial DNA structures that, when combined with antibodies, guide the immune system to target cancer cells specifically.
This study explores cell survival, the continuous repair of DNA breaks is crucial. Failure to repair DNA effectively can result in mutations, contributing to the development of cancer.
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
New Salk Institute, US, research could lead to the development of new HIV therapeutics that overcome resistance to existing drugs.
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
US investigators find that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
Swedish study reveals a significant link between specific gut bacteria and the development of coronary atherosclerotic plaques, a leading cause of heart attacks.
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.